Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases.

Nafsika Gerolymatou Athanasios-Dimitrios Bakasis Paraskevi Vasileios VoulgariPanayiotis G Vlachoyiannopoulos

Published in: The Journal of rheumatology (2022)

These data show a favorable outcome and acceptable safety profile of the 2 oral antiviral therapies MP and NM/R among a high-risk SARD population. However, cases of COVID-19 rebound are being increasingly identified. These findings call for continuous surveillance to capture the real-world efficacy and safety profiles in our subpopulations of interest.

Keyphrases

coronavirus disease
sars cov
public health
multiple sclerosis
respiratory syndrome coronavirus
electronic health record
drug induced
combination therapy
data analysis
artificial intelligence